Cogent Biosciences Inc
Change company Symbol lookup
Select an option...
COGT Cogent Biosciences Inc
TSLA Tesla Inc
TOL Toll Brothers Inc
LHAA Lerer Hippeau Acquisition Corp
PSUD Petrosun Inc
ADIL Adial Pharmaceuticals Inc
CGNT Cognyte Software Ltd
XP XP Inc
TRMD Torm PLC
INVA Innoviva Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cogent Biosciences, Inc. is a biotechnology company that is focused on developing precision therapies for genetically defined diseases. The Company’s most advanced clinical program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases. The Company has initiated APEX, a Phase II clinical study of bezuclastinib in patients with AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib. It also initiated Peak, a randomized, open-label, global Phase III clinical trial.

Closing Price
$14.02
Day's Change
-0.87 (-5.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
14.72
Day's Low
13.77
Volume
(Light)
Volume:
780,304

10-day average volume:
1,431,147
780,304

Display:

Providers:

UpdateCancel
4 providers

No news found.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.